Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Shares of IQVIA Holdings Inc. IQV rose 1.58% to $153.48 Friday, on what proved to be an all-around favorable trading session ...

Even with more restrictive assumptions, the analysis still showed a substantial treatment gap, with only 14.2% of patients ...

Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 ...

The company's approved ANDA is therapeutically equivalent to AstraZeneca Pharmaceuticals's Brilinta Tablets, 60 mg and 90 mg, it added.

Children and young adults with depression, schizophrenia, ADHD, asthma and epilepsy can get great relief from medications to ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

Shares of IQVIA Holdings Inc. IQV shed 2.56% to $151.10 Thursday, on what proved to be an all-around great trading session ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.

IQVIA Holdings Inc. IQV will release its first-quarter 2025 results on May 6, before market open. IQV has a decent earnings ...

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast for the fourth time, betting on strong demand for costly specialty medicines and branded drugs.